Study on Gynecological Laparoscopy Under Total Intravenous Anesthesia
NCT ID: NCT06524596
Last Updated: 2024-07-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
59 participants
INTERVENTIONAL
2022-01-01
2023-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Propofol-butorphanol Anesthesia During Uterine Curettage
NCT00795314
Timing of Rocuronium After Induction With Propofol on Temporal Summation of Pain
NCT04547608
Intravenous Versus Intraperitoneal Instillation of Ondansetron for Decreasing Incidence of Nausea and Vomiting After Laparoscopic Gynecological Surgeries.
NCT05317611
Comparison of the Effects of Fentanyl, Oxycodone, Butorphanol on Gastrointestinal Function
NCT04295109
Etomidate Induction in Hysteroscopic Surgery
NCT05520645
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
the butorphanol group
0.02 mg/kg of tartaric acid butorphanol intravenously 30 minutes prior to anaesthesia induction.
tartaric acid butorphanol
The group received 0.02 mg/kg tartaric acid butorphanol intravenously over 5 minutes, 30 minutes before anaesthesia induction
propofol and remifentanil
Anaesthesia was induced with 2 mg/kg propofol and 0.6 μg/kg remifentanil and maintained with a target-controlled infusion (TCI) of propofol and remifentanil, using the Marsh and Minto models, respectively.
the control group
0.02 mg/kg of normal saline intravenously 30 minutes prior to anaesthesia induction.
normal saline
The group received 0.02 mg/kg normal saline intravenously over 5 minutes, 30 minutes before anaesthesia induction
propofol and remifentanil
Anaesthesia was induced with 2 mg/kg propofol and 0.6 μg/kg remifentanil and maintained with a target-controlled infusion (TCI) of propofol and remifentanil, using the Marsh and Minto models, respectively.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
tartaric acid butorphanol
The group received 0.02 mg/kg tartaric acid butorphanol intravenously over 5 minutes, 30 minutes before anaesthesia induction
normal saline
The group received 0.02 mg/kg normal saline intravenously over 5 minutes, 30 minutes before anaesthesia induction
propofol and remifentanil
Anaesthesia was induced with 2 mg/kg propofol and 0.6 μg/kg remifentanil and maintained with a target-controlled infusion (TCI) of propofol and remifentanil, using the Marsh and Minto models, respectively.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* undergoing elective gynaecological laparoscopy for benign diseases
Exclusion Criteria
* had chronic pain or opioid use
* had a history of substance abuse or psychiatric disorders
* were pregnant or lactating
* had a severe cardiovascular, respiratory, renal, hepatic or haematological disease
* had a body mass index \>30 kg/m2
* had an inability to understand or cooperate with study procedures
33 Years
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wuhan Children's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xiang Wang
MM
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wuhan Children's hospital
Wuhan, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WHCH-008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.